POAI boasts unique historical database documenting actual drug responses of tumors – the largest in the world with over 150,000 tumors across 137 types Drug discovery funding for subsidiary Helomics planned through relationships with large pharmaceutical companies Company planning to acquire two new biological firms in the precision medicine space Predictive Oncology Inc. (NASDAQ: POAI) … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Tuesday announced the completion of the acquisitions of two wholly owned subsidiaries of InventaBioTech, Inc., Soluble Therapeutics, Inc. and BioDtech, Inc. Included in the acquisition were certain intellectual property relating to contract research organization (“CRO”) … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Acquires Soluble Therapeutics, Inc. and BioDtech, Inc.”
POAI addresses pressing need for a multi-omic approach in field of precision medicine Global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 Predictive Oncology’s ‘claim to fame’ is its inventory of over 150,000 tumors covering over 137 types of cancer, with over 30,000 related to ovarian cancer In … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space”
Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is leveraging its proprietary database of more than 150,000 tumor genomic and drug response profiles to improve cancer outcomes. An article discussing the company reads, “With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Applies Unique Database to Improve Cancer Outcomes”
Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive NNW interview with Stuart Smith (http://nnw.fm/54qVZ). An article discussing the interview reads, “During the interview, Schwartz pointed out that Helomics’ collection of more than 150,000 cancer tumors is the largest inventory of its kind … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Subsidiary Holds Unique Cancerous Tumor Inventory”
Predictive Oncology (NASDAQ: POAI) recently entered an agreement with POAI CEO Dr. Carl Schwartz to exchange a $2.1 million promissory note for newly issued equity (http://nnw.fm/Y1UeQ). An article discussing the company reads, “‘This agreement enables the company to strengthen its balance sheet and simplify its capital structure at a critical juncture in our quest to commercialize … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Exchanges $2.1M Promissory Note for Common Stock”
POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes”
Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID19 vaccine with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter. According to the update, the ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10, … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Vaccine Development Race Through Acquisition, Subsequent Partnership/Licensing of Ground-Breaking Technology”
POAI CEO exchanges $2.1 million promissory note for newly issued stock shares Strategic agreement enables company to strengthen balance sheet, simplify capital structure in plan to commercialize highly valuable database Because of its unique patient inventory, Helomics is only company with ability to profile tumors In a significant move indicating strong confidence in the company’s … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) CEO Enters into Debt-to-Equity Agreement, Touts Company’s Major Asset”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,396,826 shares of its common stock. According to the update, the shares are each … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces At-The-Market Priced $2.2M Registered Direct Offering”
